RA Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

RA Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.2M	Hold	5,049,779	–	–	0.58%	34
2026 Q1	$47M	Sell	5,049,779 -603,432	-11%	-$5.25M	0.5%	36
2025 Q4	$42.4M	Buy	5,653,211 +1,090,000	+24%	+$11.1M	0.43%	39
2025 Q3	$39.7M	Hold	4,563,211	–	–	0.49%	33
2025 Q2	$16.9M	Hold	4,563,211	–	–	0.29%	40
2025 Q1	$14.7M	Hold	4,563,211	–	–	0.25%	57
2024 Q4	$25.4M	Sell	4,563,211 -535,000	-10%	-$4.2M	0.34%	49
2024 Q3	$55.1M	Hold	5,098,211	–	–	0.64%	35
2024 Q2	$107M	Buy	5,098,211 +46,700	+0.9%	+$1.17M	1.42%	21
2024 Q1	$161M	Buy	5,051,511 +888,300	+21%	+$22.7M	2.05%	12
2023 Q4	$84.3M	Hold	4,163,211	–	–	1.32%	22
2023 Q3	$53M	Buy	4,163,211 +1,093,680	+36%	+$18.3M	1.04%	28
2023 Q2	$55.5M	Buy	+3,069,531	New	+$56.5M	1.05%	29

Other funds holding FDMT

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RA Capital Management's FDMT Position: Q2 2026 in Review

RA Capital Management held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 5,049,779 shares worth $67.2M. The position accounts for 0.58% of the portfolio, ranked #34.

RA Capital Management first reported a position in FDMT in Q2 2023 and has held it in 13 quarters since. The position peaked at $161M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

RA Capital Management held 5,049,779 shares of 4D Molecular Therapeutics worth $67.2M as of Q2 2026.
RA Capital Management left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
4D Molecular Therapeutics made up 0.58% of RA Capital Management's portfolio in Q2 2026, its #34 holding.
RA Capital Management first reported a position in 4D Molecular Therapeutics in Q2 2023 and has held it in 13 quarters since.
RA Capital Management's 4D Molecular Therapeutics position peaked at $161M in Q1 2024.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.